The US Food and Drug Administration (FDA) has approved the InnovaBurn placental extracellular matrix (ECM) medical device from Convatec.
This device is intended to manage complex surgical wounds and burns, including partial-thickness second-degree burns.
Part of the InnovaMatrix platform, InnovaBurn is a xenograft controlled for genetic variability as well as environmental and lifestyle factors, such as diet and activity levels.
The new device can be used to manage traumatic lacerations, dehisced incisional wounds, pressure and venous ulcers, post-surgical incisions, post-Mohs surgical wounds, and diabetic ulcers.
According to the company, InnovaBurn does not need preparation, specific placement orientation, tissue tracking or special storage.
Furthermore, the device is said to adhere and conform to wound sites.
InnovaMatrix claims to be the first and only placental-derived medical device developed to manage burns as well as complex surgical and hard-to-heal wounds.
Produced using Convatec’s TriCleanse process, InnovaMatrix products, including the new InnovaBurn ECM, provide physicians with reproducible devices that sustain the inherent benefits of the placenta.
Convatec US Burn Division sales director Debra Noble said: “InnovaBurn is an innovative advancement in ECM technology for patients with partial-thickness, second-degree burns.
“InnovaBurn allows burn patients the benefits of the latest and best placental ECM technology. Our unique source material helps us to manufacture some of the largest ECM sizes in the industry much more affordably, so more patients have access to this brand new technology.
“Physicians tell us they appreciate the special sizing and InnovaBurn’s ease of use that help them manage larger wounds like burns.”